Raul Cavalcante Maranhao

• Abstract

  In world pioneer studies, we showed nanoparticles (LDE) similar to the lipid structure of low-density lipoprotein (LDL) can concentrate anti-cancer agents, such as paclitaxel, etoposide, and methotrexate, in neoplastic and inflamed tissues. Using LDE as carrier, the toxicity of those agents was drastically reduced, whereas the pharmacologic actions were enhanced. The near-absence of toxic…

  Lipid core nanoparticles (LDE) as vehicles of chemotherapeutic agents: a new standard for the medical therapeutics, AP.TEM

• Abstract

  The Liquid Scintillation Counter is key equipment in our Laboratory to carry out the studies on HDL metabolism, lipid transfer, pharmacokinetics and biodistribution, cholesterol efflux and cellular uptake of drugs and nanoparticles, proposed in the sub-projects of this Thematic Project. (AU)

  Multi-User Equipment approved in grant 2014/03742-0: Liquid Scintilation Counter, AP.EMU

• Technological improvement in the production of LDE nanoparticles carrying drugs: increase in production scale and technical training to maintain product quality., BP.TT

• Abstract

  In previous studies, we demonstrated that lipid nanoparticles with a lipid structure similar to low-density lipoprotein (LDL), termed LDL-like nanoparticles (LDE), accumulate in transplanted rabbit hearts. When rabbits with cardiac transplants, a model of graft vascular disease (GVD), were treated with the chemotherapeutic agent paclitaxel associated with LDE, there was a notable reductio…

  Treatment of Graft Vascular Disease with paclitaxel-loaded lipid nanoparticles: effects on inflammatory markers and plasma lipids, functional aspects of HDL, and serum MicroRNAs, BP.DR

• Abstract

  The production of nanoparticles, named by LDE, in our laboratory is already well standardized for some chemotherapeutics, such as paclitaxel, docetaxel, daunorubicin, etoposide and methotrexate. The modification of the chemical structure of the drug by esterification reactions is necessary to increase lipophilicity and ensure the incorporation of these drugs into the nanoparticles, thus o…

  Obtaining a new formulation of nanoparticles, LDE-melphalan: Synthesis of a lipophilic derivative of the chemotherapeutic agent, preparation of lipid nanoparticles and incorporation, stability, cytotoxicity and in vivo pharmacological tests., BP.PD

(Only some records are available in English at this moment)